

11-146-C025

Monoclonal Antibody to CD184 / CXCR4 Purified Antibody (0.025 mg)

Clone:	12G5
Isotype:	Mouse IgG2a
Specificity:	The mouse monoclonal antibody 12G5 recognizes CD184, a 45 kDa G-protein-linked CXC chemokine receptor widely expressed on blood and tissue cells. HLDA 7; WS Code 70204
Regulatory Status:	RUO
Immunogen:	CP-MAC-infected Sup-T1 cells
Species Reactivity:	Human, Non-Human Primates
Application:	Flow Cytometry Immunohistochemistry (paraffin sections) Immunocytochemistry Functional Application blocking
Purity:	> 95% (by SDS-PAGE)
Purification:	Purified by protein-A affinity chromatography
Concentration:	1 mg/ml
Storage Buffer:	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability:	Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD184, also known as CXCR4 or fusin, is a receptor for the C-X-C chemokine SDF-1. It is expressed mainly in hematopoietic cells, vascular endothelium, and neural tissue. CD184 is a G-protein coupled receptor containing extracellular N-terminal, seven transmembrane domains and intracellular C-terminal domain. It transduces signal by increasing the intracellular calcium level. CD184 plays an essential role in vascularization of the gastrointestinal tract, and is involved in cerebellar development and in hematopoiesis. It is also a coreceptor (with CD4) for HIV-1 X4 virus and a primary receptor for some HIV-2 isolates.

For laboratory research only, not for drug, diagnostic or other use.



Antibodies

References:

*Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S, Pogacic V, Villa A, Ehret S, Berridge G, Spoo A, Dierks C, Biondi A, Knapp S, Duyster J, Schwaller J: Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. *J Exp Med.* 2009 Aug 31;206(9):1957-70.

*Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF: A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. *Blood.* 2012 Apr 26;119(17):3917-24.

*Campioni D, Zauli G, Gambetti S, Campo G, Cuneo A, Ferrari R, Secchiero P: In vitro characterization of circulating endothelial progenitor cells isolated from patients with acute coronary syndrome. *PLoS One.* 2013;8(2):e56377.

*Koopman G, Mortier D, Hofman S, Koutsoukos M, Bogers WM, Wahren B, Voss G, Heeney JL: Acute-phase CD4⁺ T-cell proliferation and CD152 upregulation predict set-point virus replication in vaccinated simian-human immunodeficiency virus strain 89.6p-infected macaques. *J Gen Virol.* 2009 Apr;90(Pt 4):915-26.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz